Inventiva SA ADR (IVA)
NASDAQ:IVA
Want to see IVA full AI Analyst Report?
IVA Stock Chart & Stats
$5.67
-$0.02(-0.90%)
At close: 4:00 PM EST
$5.67
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$2.85 - $7.98
Previous CloseN/A
Volume917.00
Average Volume (3M)226.36K
Market Cap
$1.04B
Enterprise Value$556.42M
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Sep 25, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding209,007,480
10 Day Avg. Volume176,246
30 Day Avg. Volume226,358
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-25.46
Price to Sales (P/S)164.91
P/FCF Ratio-7.30
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue124.12
Enterprise Value/Gross Profit352.01
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$15.75Price Target Upside177.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$4.18M
Bulls Say, Bears Say
Bulls Say
Pivotal Trial Fully Enrolled And Well PoweredCompletion of NATiV3 enrollment and >90% statistical power materially reduces clinical execution and sample-size risk versus earlier-stage programs. A well-powered, randomized pivotal trial increases the chance of a definitive regulatory readout and clearer go/no-go decisions that drive long-term development and partnering timelines.
Material Near-term Cash Runway From Recent FinancingsA strong cash balance funded largely by structured financing and a U.S. offering supports completion of the Phase III program and near-term pre-commercial investments. This reduces immediate financing pressure ahead of the Q4 2026 readout and gives management runway to execute regulatory and outcome-trial planning prior to commercialization steps.
Differentiated Product Profile With Expedited Regulatory DesignationsPhase II efficacy signals plus Breakthrough and Fast Track designations are durable structural advantages: they support an accelerated regulatory pathway and highlight a multi-dimensional product profile (fibrosis, MASH resolution, HbA1c and lipids) that can broaden clinical utility and payer/commercial arguments if Phase III confirms benefit.
Bears Say
Persistent Operating Losses And Rising Cash BurnSustained large operating losses and negative operating cash flow indicate the business runs structural cash deficits. Continued cash burn forces recurring financing, constrains long-term investment flexibility and elevates dilution risk, making the company dependent on capital markets timing and successful clinical outcomes to sustain operations beyond the pivotal readout.
Weakened Balance Sheet: Negative Equity And Higher DebtNegative shareholder equity and rising leverage materially weaken financial flexibility and increase insolvency risk under stress. A compromised capital structure raises the cost of additional funding, limits strategic alternatives like mergers or asset sales on favorable terms, and can constrain long-term planning if clinical or commercial progress stalls.
Funding Dependent On Contingent Tranche/warrant MechanicsReliance on contingent warrant exercise ties material future liquidity to market/clinical conditions and third-party decisions. If tranche mechanics fail to deliver, the company will need fresh financing before commercialization—likely dilutive or expensive—creating a persistent execution and planning risk that affects long-term strategic options and partner negotiations.
Inventiva News
IVA FAQ
What was Inventiva SA ADR’s price range in the past 12 months?
Inventiva SA ADR lowest stock price was $2.85 and its highest was $7.98 in the past 12 months.
What is Inventiva SA ADR’s market cap?
Inventiva SA ADR’s market cap is $1.04B.
When is Inventiva SA ADR’s upcoming earnings report date?
Inventiva SA ADR’s upcoming earnings report date is Sep 25, 2026 which is in 114 days.
How were Inventiva SA ADR’s earnings last quarter?
Inventiva SA ADR released its earnings results on Mar 30, 2026. The company reported -$1.067 earnings per share for the quarter, missing the consensus estimate of -$0.279 by -$0.788.
Is Inventiva SA ADR overvalued?
According to Wall Street analysts Inventiva SA ADR’s price is currently Undervalued.
Does Inventiva SA ADR pay dividends?
Inventiva SA ADR does not currently pay dividends.
What is Inventiva SA ADR’s EPS estimate?
Inventiva SA ADR’s EPS estimate is -0.38.
How many shares outstanding does Inventiva SA ADR have?
Inventiva SA ADR has 209,007,480 shares outstanding.
What happened to Inventiva SA ADR’s price movement after its last earnings report?
Inventiva SA ADR reported an EPS of -$1.067 in its last earnings report, missing expectations of -$0.279. Following the earnings report the stock price went up 1.277%.
Which hedge fund is a major shareholder of Inventiva SA ADR?
Currently, no hedge funds are holding shares in IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (177.78% Upside)
$15.75 (177.78% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.64%
12-Months-Change
Fundamentals
Return on Equity
1870.38%
Trailing 12-Months
Asset Growth
138.07%
Trailing 12-Months
Company Description
Inventiva SA ADR
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive and execution-focused picture: major operational milestones were achieved (NATiV3 enrollment completion, >1,000 patients, clear Q4 2026 readout target), a solid near-term cash position (EUR 230.9M), conservative powering (>90%) and organizational strengthening for regulatory/commercial readiness. Key risks remain—funding beyond the stated runway depends on tranche/warrant mechanics or future financing, tolerability (weight gain/fluid retention) is a known class risk to be monitored, endpoints have inherent variability, and competition is active. On balance the call emphasized progress, readiness and a clear pathway to a potentially pivotal readout while acknowledging material clinical and financing dependencies.View all IVA earnings summariesIVA Stock 12 Month Forecast
Average Price Target
$15.75
▲(177.78% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
0.55% Mutual Funds
18.58% Other Institutional Investors
80.76% Public Companies and Individual Investors